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Mammalian target of rapamycin (mTOR) is a central
controller of cell growth. mTOR assembles into two
distinct multiprotein complexes called mTOR complex
1 (mTORC1) and mTORC2. Here we show that the
mTORC1 component raptor is critical for muscle func-
tion and prolonged survival. In contrast, muscles
lacking the mTORC2 component rictor are indistin-
guishable from wild-type controls. Raptor-deficient
muscles become progressively dystrophic, are im-
paired in their oxidative capacity, and contain in-
creased glycogen stores, but they express structural
components indicative of oxidative muscle fibers. Bio-
chemical analysis indicates that these changes are
probablydueto lossofactivationof directdownstream
targets of mTORC1, downregulation of genes involved
in mitochondrial biogenesis, including PGC1a, and hy-
peractivation of PKB/Akt. Finally, we show that activa-
tion of PKB/Akt does not require mTORC2. Together,
these results demonstrate that muscle mTORC1 has
an unexpected role in the regulation of the metabolic
properties and that its function is essential for life.
INTRODUCTION
Growth of an organ during development and during adaptation in
the adult can be controlled by alterations in either the number or
the size of cells. The two mechanisms are fundamentally differ-
ent and require distinct regulation. Rapamycin is a cell growth in-
hibitor used to treat a number of clinical indications including
graft rejection and cancer (Tsang et al., 2007). The molecular
target of rapamycin is a Ser/Thr kinase, called TOR in yeast
(Heitman et al., 1991) or mTOR in mammals. The evolutionarily
conserved TOR pathway controls many cellular processes, in-
cluding protein synthesis, ribosome biogenesis, nutrient trans-
port, and autophagy (reviewed in Wullschleger et al., 2006).
mTOR assembles into two distinct multiprotein complexes,
termed mTORC1 and mTORC2 (Jacinto et al., 2004; Sarbassov
et al., 2004). mTORC1 consists of raptor (regulatory associated
protein of mTOR), mLST8, PRAS40, and mTOR (Wullschleger
et al., 2006) and is sensitive to rapamycin. mTORC2 consistsCelof rictor (rapamycin insensitive companion of mTOR), mSIN1,
mLST8, and mTOR (Jacinto et al., 2004; Sarbassov et al., 2004).
Changes in thesizeofadultmuscle, in response toexternal stimuli,
are mainly due to the growth of individual muscle fibers and not an
increase in fiber number (Glass, 2005). As mTOR controls cell
growth, it has also been implicated in the control of muscle mass.
For example, rapamycin inhibits recovery of skeletalmuscle fromat-
rophy (Bodine et al., 2001). Moreover, activation of the mTORC1-
upstreamcomponentPKB/Akt inducesmusclehypertrophy (Bodine
et al., 2001; Pallafacchina et al., 2002; Izumiya et al., 2008), and this
increase is rapamycin sensitive (Izumiya et al., 2008). Conversely,
muscle fibers of mice deficient for the mTOR downstream target
S6kinase1 (S6K1)areatrophic (Ohannaetal.,2005). Incontrast, little
is known of the function of rapamycin-insensitive mTORC2, whose
primary readouts are thought to be the organization of the actin cy-
toskeleton. Moreover, mTORC2 has been shown to be the kinase
that phosphorylates PKB/Akt on Ser473 (Sarbassov et al., 2005).
To circumvent the early embryonic lethality of mice deficient for
raptor or rictor (Guertin et al., 2006; Shiota et al., 2006), we gener-
atedmice with floxed raptor or rictor alleles. Here we describe the
phenotype of mice that lack raptor (i.e., mTORC1), rictor (i.e.,
mTORC2), or both proteins specifically in skeletal muscle. We
find thatdeletionofmTORC2doesnotcauseanovertmusclephe-
notype. In contrast, mTORC1-deficient musclesmanifest signs of
atrophy and become progressively dystrophic. Moreover, mus-
cles behavemetabolically like fast-twitch, glycolytic skeletalmus-
clebut exhibit structural featuresandcontractionproperties indic-
ative of slow-twitch, oxidativemuscle fibers. Biochemical analysis
indicates that this phenotype can be accounted for by the ab-
senceof phosphorylation of the immediatemTORC1downstream
targets S6K/S6 and 4EBP1, the downregulation of PGC1a, and
hyperphosphorylation of PKB/Akt. Finally, deficiency of both rap-
tor and rictor results in a phenotype indistinguishable from that of
muscles lacking only raptor. Importantly, PKB/Akt is still hyper-
phosphorylatedunder theseconditions, suggesting thatmTORC2
is not the only kinase able to phosphorylate PKB/Akt on Ser473.
RESULTS
Skeletal Muscle-Specific Ablation of raptor and rictor
To examine the function of raptor and rictor in skeletal muscle we
usedtheCre-loxPrecombinationsystem.To thisend,we introduced
loxP sites into the raptor locus and the rictor locus (Figure 1A). Inl Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc. 411
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Role of mTORC1 and mTORC2 in Skeletal MuscleFigure 1. Targeting Strategy and Initial Characterization of RAmKO and RImKO Mice
(A) Schematic presentation of wild-type and targeted alleles of raptor (left panel) and rictor (right panel) before and after recombination. Localization and size of
DNA fragments generated by particular restriction digests are indicated. Probes used for Southern blot analysis are shown by hatched bars. PCR primers for
genotyping are indicated by arrows. +: wild-type allele; fl-neo: targeted allele; fl: alleles after recombination by Flp; -: alleles after recombination by Cre.
(B) Southern blot analysis of genomic DNA from ES cells and F1 progeny of resulting chimeras. Correct targeting of the 50 end is indicated by the presence of a
6.0 kb band in the raptor locus and a 7.3 kb band in the rictor locus. Correct targeting at the 30 end is indicated by a 6.1 kb band and a 7.3 kb band. In each blot of
ES cells, wild-type is to the left.
(C) Western blot analysis of protein extracts from skeletal muscle of RAmKO and RImKO mice. Controls correspond to muscle extracts from mice that carry the
floxed alleles but are negative for HSA-Cre. Equal protein loading is confirmed by blotting for a-actinin.
(D) Growth curve of RAmKO, RImKO, and control mice. Mice of each genotype were weighed every week. A significant difference between RAmKO and control
mice (p < 0.05) was observed after the age of 63 days. Individual data points represent means ± SEM (n = 5 for RAmKO; n = 3 for RImKO; n = 10 for controls).
(E) Photograph of 140-day-old RAmKO, control (ctrl), and RImKO mice.
(F) Survival curve of RAmKO, RImKO, and control mice.412 Cell Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc.
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Role of mTORC1 and mTORC2 in Skeletal MuscleTable 1. Analysis of Particular Tissues in Control and RAmKO Mice
90 day 140 day
ctrl RAmKO ctrl RAmKO
Tibia length (cm) 2.0 ± 0.1 2.0 ± 0.1 2.0 ± 0.1 2.1 ± 0.1
Lower hindleg (mg) 449.2 ± 19.3 344.0 ± 11.4*** 428.0 ± 28.0 331.6 ± 41.3**
Triceps brachii (mg) 98.3 ± 11.3 67.0 ± 10.4*** 89.5 ± 14.0 68.8 ± 13.8*
Soleus (mg) 9.7 ± 0.8 7.4 ± 0.6*** 9.2 ± 0.8 7.1 ± 1.2*
EDL (mg) 12.7 ± 0.8 10.3 ± 0.7*** 12.0 ± 0.7 9.4 ± 1.4*
Tibialis anterior (mg) 58.3 ± 2.7 40.8 ± 2.3*** 55.6 ± 1.8 39.0 ± 1.3***
Epididymal fat pad (mg) 566.4 ± 214.9 438.9 ± 93.1 616.0 ± 194.8 242.5 ± 118.7**
Heart (mg) 85.12 ± 6.6 68.1 ± 4.1* 88.5 ± 2.1 72.1 ± 4.4**
Liver (mg) 1350.9 ± 185.0 1187.5 ± 161.0 1232.0 ± 187.5 1055.0 ± 269.1
Weight or lengthwasmeasured for different muscles, bones, and other organs in 90- and 140-day-oldmice. p values determined by Student’s t test are
indicated by asterisks (n = 4 mice). Values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.both cases, Cre-mediated recombination causes a frame shift
and early stop of translation. In addition, Flp recognition target
(FRT) sites were inserted that flanked a neomycin resistance
cassette for the selection of targeted embryonic stem (ES) cells.
This cassette was removed using Flp deleter mice (Figure 1A;
Rodriguez et al., 2000). Southern blot analysis confirmed suc-
cessful targeting in ES cells and germline transmission of result-
ing chimeras (Figure 1B). Mice homozygous for the floxed allele
(raptorfl/fl or rictorfl/fl) were mated with heterozygous floxed mice
that also expressed Cre recombinase under the control of the
muscle-specific human skeletal actin (HSA) promoter (Schwan-
der et al., 2003). Mice positive for the HSA-Cre transgene that
also carried two floxed alleles were then analyzed. For simplicity,
we refer to HSA-Cre; raptorfl/fl as RAmKO (for raptor muscle
knockout) and to HSA-Cre; rictorfl/fl as RImKO (for rictor muscle
knockout) mice. Successful recombination of raptor or rictorwas
confirmed by PCR on genomic DNA isolated from tibialis muscle
(Figure S1A available online). Western blot analysis of RAmKO
and RImKO skeletal muscle revealed a strong reduction of the
respective proteins (Figures 1C and S1B; Table S1). Residual ex-
pression of these proteins in knockout muscle is not due to leaky
recombination of the targeted allele as raptorfl/fl or rictorfl/fl mice
crossed to other Cre-expressing mice led to a complete loss of
the respective protein in the targeted tissue (Figure S1B; Polak
et al., 2008; M.N. Hall, personal communication). Thus, the low
levels of raptor and rictor protein that were detected in the
RAmKO and RImKO muscles are ascribable to the expression
of raptor or rictor in nontargeted cells, such as fibroblasts, satel-
lite cells, Schwann cells, and peripheral nerves, which are also
contained in skeletal muscle.
Neither RAmKO nor RImKO mice showed an overt phenotype
in the first weeks of life. Starting at the age of approximately
5 weeks, RAmKO mice could be distinguished from their litter-
mates by their lower body weight. The difference became sig-
nificant after day 63, and the mice remained lighter throughout
life (Figure 1D). In contrast, the body weight of RImKO mice did
not differ significantly from controls, although at higher age
RImKO mice were slightly heavier (Figure 1D). For both RAmKO
and RImKO mice, the food consumption was comparable to
controls (Figure S1C and data not shown). RAmKO mice devel-Cell Moped a pronounced kyphosis starting at the age of approxi-
mately 2 months and became markedly lean (Figures 1E and
S1D). In contrast, RImKO mice appeared normal. Finally,
RAmKO mice began to die at the age of 110 days, and none
survived for more than 190 days (Figure 1F). RImKO mice did
not die prematurely (the oldest RImKO mice now being more
than 2 years old).
To examine whether the difference in weight gain was based
on reduced muscle mass in RAmKO mice, we weighed different
muscles and several other organs at day 90 (i.e., before the mice
showed a severe phenotype) and at day 140. As shown in
Table 1, all the muscles measured were significantly lighter in
90- and 140-day-old RAmKO mice compared to controls. As
RAmKO mice appeared lean (Figure 1E) and only little or no fat
was detected in older mice (Figure S1D), we also weighed the
epididymal fat pads. Indeed, RAmKO mice contained signifi-
cantly less adipose tissue at the age of 140 days (Table 1). The
loss of adipose tissue does not seem to be due to changes in mi-
tochondrial uncoupling properties as the body temperature of
RAmKO mice was not different from those of control littermates
(Figure S1E). The weight of the liver was indistinguishable from
controls whereas hearts were again lighter (Table 1). The left ven-
tricle mass of the heart, however, correlated with the difference
in body weight (Figure S1F), indicating that the difference in heart
weight is probably due to allometric scaling (Popovic et al.,
2005). Moreover, the ejection fraction determined by echocardi-
ography was indistinguishable from littermate controls (data not
shown). Finally, we could not detect any recombination events in
the hearts of RAmKOmice (Figure S1A). Our data therefore show
that raptor deficiency in skeletal muscle causes a progressive,
disproportional loss of skeletal muscle and fat.
Deficiency of mTORC1 but Not mTORC2 Causes Muscle
Dystrophy
Kyphosis and early death are often signs of muscle dystrophy
(Laws and Hoey, 2004). We therefore examined different skeletal
muscles of RAmKO and RImKOmice using hematoxylin and eo-
sin (H&E) staining. No change in the overall architecture of soleus
and extensor digitorum longus (EDL) muscles was found in
RImKO mice (Figure 2A). Muscles from RAmKO mice showedetabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc. 413
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Role of mTORC1 and mTORC2 in Skeletal MuscleFigure 2. Muscles of RAmKO Mice Show Signs of a Progressive Dystrophy
(A) Hematoxylin and eosin (H&E) staining of muscle cross-sections from the EDL and soleus (Sol) muscle of 140-day-old mice. In EDL muscle of RAmKO mice,
some large (blue arrowheads) but also small fibers are present. Centralized nuclei (white arrowheads) and central core-like structures (black arrowheads) can be
found in soleus muscle of RAmKO mice. Both muscles contain many mononuclear cells (green arrowheads).
(B) Longitudinal section of soleusmuscle of a 140-day-old RAmKOmouse. Besides centrally aligned nuclei (white arrowheads), central core-like structures (black
arrowheads), which expand longitudinally in muscle fibers, are visible.
(C–F) Fiber sizedistribution in the soleusmuscle of 90-day- (C) and140-day-old (D) and in theEDLmuscle of 90-day- (E) and140-day-old (F)RAmKOandcontrolmice.414 Cell Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc.
Cell Metabolism
Role of mTORC1 and mTORC2 in Skeletal Musclesigns of a dystrophy, such as mononuclear cells (green arrow-
heads) and a high number of small and large muscle fibers
(blue arrowheads). In soleus muscle and to a lower extent in
EDL, we also found muscle fibers with centralized nuclei (white
arrowheads), indicative of ongoing de- and regeneration, and
structures reminiscent of central cores (black arrowheads in Fig-
ures 2A and 2B). Quantification showed that the fiber size distri-
bution was strongly altered in both soleus and EDL muscle (Fig-
ures 2C–2F). In addition, the number of centralized myonuclei
(Figure 2G) and the relative percentage of muscle fibers with
the central core-like structures (Figure 2H) were higher in
RAmKO mice compared to controls. Dystrophic hallmarks
seemed more pronounced in soleus than in EDL muscle. Inter-
estingly, the severity of the dystrophy correlated with the high
endogenous expression of raptor, rictor, mTOR, or PKB/Akt in
wild-type soleus muscle (Figure S2A). Muscles of RAmKO
mice also showed increased immunoreactivity for tenascin-c
and f4/80 (Figure S2B), which mark fibrotic tissue (Ringelmann
et al., 1999) and infiltrating macrophages (Austyn and Gordon,
1981), respectively. However, other dystrophic hallmarks includ-
ing increased uptake of Evans blue into muscle fibers and in-
creased levels of creatine kinase in the blood could not be de-
tected (Figure S2C and data not shown). Similarly, the number
of muscle fibers was not changed in soleus muscle of RAmKO
mice compared to controls (Figure S2D). Neuromuscular junc-
tions of RAmKO mice were indistinguishable from those in con-
trol mice (Figure S2E). Probably due to ongoing de- and regener-
ation, many extrasynaptic acetylcholine receptor (AChR)
clusters could be detected in the diaphragm of RAmKO mice
(Figure S2F). Based on the extensive muscle wasting and the
high degree of fibrosis, the dystrophy was particularly severe in
the diaphragm of older mice (Figure 2I), suggesting that respira-
tory failure might be the cause of premature death. In contrast to
RAmKO mice, muscles of RImKO mice did not show any alter-
ations in fiber size (Figure S3A) and in the cytoskeletal organiza-
tion as indicated by the sarcomeric arrangement of a-actinin
(Figure S3B). In summary, our data show that ablation of raptor
and thus of mTORC1, but not of rictor, results in a progressive
muscle dystrophy.
Skeletal Muscles of RAmKO Mice Show Alterations
in Their Metabolic and Structural Properties
One of the first observations we made during the course of this
work was that muscles of RAmKO mice appeared paler than
those of RImKO or control mice. This difference was particularly
striking for the soleusmuscle (Figure 3A, arrowhead) andwas not
based on decreased vascularization, as revealed by staining for
laminin-a5 (data not shown), which is expressed in blood vessels
(Sorokin et al., 1997). To test for changes in mitochondrial func-
tion, we used an NADH-tetrazolium (NADH-TR) staining. Indeed,
the activity of oxidative enzymes appeared lower in both EDL
and soleusmuscles of RAmKOmice (Figure 3B). Fibers with cen-
tral core-like structures, which were completely devoid of
NADH-TR reactivity, could be found in RAmKO soleus muscleCell(black arrowheads). Such a lack of NADH staining is a diagnostic
feature of central core disease (Sewry et al., 2002). To further test
whether the changes in NADH-TR reactivity involved mitochon-
dria, we also examined longitudinal sections of soleusmuscle by
electron microscopy. Muscle of RAmKO mice was distinguish-
able from control muscle by a substantial loss of intermyofibrillar
mitochondria, which are normally localized perpendicular to the
Z disks (arrows in upper panel, Figure 3C). Only few intermyofi-
brillar mitochondria remained (arrow lower panel, Figure 3C).
Moreover, mitochondria localized in the subsarcolemmal space
seemed more densely packed and swollen in RAmKO mice
(Figure S4A). As a decrease in oxidative properties is often ac-
companied by a compensatory increase in glycolytic activity,
we performed a periodic acid-Schiff (PAS) staining. Indeed, the
glycogen content was increased in both EDL and soleus muscle
(Figure 3D). The increase was more pronounced in the fast-
twitch EDL muscle. The glycogen content in the gastrocnemius
muscle, which consists of a mixed population of fast- and
slow-twitch fibers, was more than five times higher than in
control mice (control: 21 ± 7 mmol glucose/g tissue; RAmKO:
108 ± 22 mmol glucose/g tissue; mean ± SEM; n = 4 mice). The
change in oxidative capacity and glycogen content in skeletal
muscle also affected overall metabolism as glucose uptake
from the blood was significantly slower in RAmKO mice com-
pared to littermate controls (Figure 3E).
High content of glycogen is indicative of fast-twitch (type II)
muscle fibers. To test whether muscles in RAmKO mice also
changed their structural properties, we stained EDL and soleus
muscle for the slow myosin heavy chain (slMHC), a marker of
slow-twitch fibers. Surprisingly, EDL and soleus muscles of
140-day-old RAmKOmice contained even more slMHC-positive
muscle fibers (Figure 3F, green) than controls, and the increase
of slMHC was regionalized in individual muscles (Figure S4B).
In both muscles, the number of slMHC-positive fibers was ap-
proximately two to three times higher than in controls (Figures
3G and 3H). In soleus muscle of RAmKO mice, almost 100%
of the fibers were positive for slMHC (Figure 3H), and this in-
crease was also seen by western blot analysis (Figure 3I; Table
S1). Moreover, other components characteristic for slow-twitch
muscle, such as the slow isoform of troponinT (slTnT) and of tro-
poninI (slTnI), were also increased in soleus muscle of RAmKO
mice (Figures 3I and 3J; Table S1). Thus, deletion of mTORC1
in skeletal muscle fibers causes a shift of their metabolic proper-
ties from oxidative to glycolytic. However, this change in themet-
abolic characteristics of muscles is opposite to their structural
properties.
Functional Characterization of Muscles in RAmKO Mice
To address whether the observed changes in metabolic and
structural characteristics had consequences on the overall per-
formance of muscle, we allowed 90-day-old mice to exercise
using voluntary wheel running. The representative activity chart
of a single mouse shows that running sessions of RAmKO mice
were shorter and less frequent than those of controls(G) Mean percentage of muscle fibers with centralized nuclei (cnf) in the soleus and EDL muscle of RAmKO and control mice.
(H) Percentage of muscle fibers containing central core-like structures (ccls) in soleus and EDL muscle of RAmKO and control mice.
(I) H&E staining of cross-sections of the diaphragms of 90-day- and 140-day-old RAmKO and control mice.
Individual data points and bars (C–H) represent means ± SEM (n = 4 mice). Scale bars (A, B, and I) = 50 mm. p values are ***p < 0.001; **p < 0.01; *p < 0.05.Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc. 415
Cell Metabolism
Role of mTORC1 and mTORC2 in Skeletal MuscleFigure 3. Metabolic and Structural Properties Diverge in Skeletal Muscle of RAmKO Mice
(A) Preparation of the entire hindleg isolated from 90-day-old mice of the genotypes indicated. Note that soleus muscle (arrowheads) is pale in RAmKO mice
compared to RImKO and control mice.
(B) Activity of oxidative enzymes examined by NADH-tetrazolium staining (blue precipitate) in EDL and soleus muscle of 140-day-old mice. Central core-like
structures devoid of NADH staining (black arrowheads) and increased subsarcolemmal reactivity (red arrowheads) were detected in some RAmKO soleus fibers.
(C) Electron micrographs of longitudinal sections of soleus muscle from 140-day-old mice. Most intermyofibrillar mitochondria in RAmKO muscle are lost from
their specific position next to Z disks (red arrows, upper panel). Remaining mitochondria in RAmKO mice show high morphologic variability (red arrow, lower
panel).
(D) Periodic acid-Schiff (PAS) staining of cross-sections from 140-day-old mice. The reaction product (magenta color) is indicative of the amount of glycogen in
the tissue.416 Cell Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc.
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Role of mTORC1 and mTORC2 in Skeletal Muscle(Figure 4A). When averaged over one week, the total distance
run per day by RAmKO mice was 60% of that of control
mice (Figure 4B), and the top running speed was significantly
lower (Figure 4C). In contrast to the aerobic wheel running
task, RAmKO mice performed as well as control animals in
a grip strength test on a horizontal grid (Figure 4D). To examine
the contraction properties of muscles, force measurements
Figure 4. Exercise Performance and Muscle
Physiology
(A) Representative activity chart with bins of 10 s from a single
95-day-old RAmKO mouse or a control mouse. Charts were
measured from 6 pm to 6 am (dark cycle).
(B) Average distance run per day determined during one week
(starting at the age of 90 days, n = 4 for RAmKO and n = 9 for
controls).
(C) Average of the top 10% speed measured over one week
(starting at the age of 90 days, n = 4 for RAmKO and n = 9
for controls).
(D) Grip strength of 90-day-old RAmKO and control mice.
Average time mice were able to hold on a horizontal grid
was normalized to body weight. Values of control mice were
set to 100% (n = 3).
(E) Force capacity resistance of EDL or soleus muscle isolated
from 140-day-old mice was measured during muscle fatigue
induced by intermittent tetanic stimulation. Trains of 150 Hz
tetani of 350 ms duration were given at 3.6 s intervals (n = 3
for RAmKO and n = 4 for control mice).
Individual data points and bars (B–E) represent means ± SEM.
p values are ***p < 0.001; **p < 0.01; *p < 0.05.
were performed on isolated EDL and soleus mus-
cles. In line with the observed increase of fibers
expressing structural proteins characteristic of
slow-twitch muscle, time to peak, half time to
peak, and relaxation time of the twitch were all in-
creased (Table 2). This difference to control mice
did not reach significance in EDL muscle but was
highly significant in soleus muscle (Table 2). Twitch
force and maximal tetanic absolute force for both
muscles were, however, significantly lower in
RAmKO mice. The decrease of absolute force ca-
pacity reflects the decrease of muscle mass
(Table 1) since there is no difference of the maxi-
mal tetanic force when normalized to the muscle
cross-sectional area (Table 2). An intermittent
maximal tetanic stimulation protocol revealed
that both EDL and soleus muscles from RAmKO
mice were more resistant to fatigue (Figure 4E).
These data indicate that raptor-deficient muscle fi-
bers have a reduced aerobic capacity (voluntary
wheel running) like fast-twitch, glycolytic muscle fi-
bers but exert contraction properties (isolated muscles) of slow-
twitch, oxidative muscle fibers.
Inactivation of raptor or rictor Affects Activation
of PKB/Akt
In search of a mechanistic explanation for the phenotypes, we
examined soleus muscle of RAmKO and RImKO mice(E) Glucose tolerance test with 65-day-old mice (n = 8 for RAmKO and n = 11 for control mice).
(F) Immunostaining for slow myosin heavy chain (slMHC; green) and the laminin g1 chain (red) of cross-section from 140-day-old mice.
(G and H) Quantification of slMHC-positive muscle fibers in soleus and EDL muscle from 90- and 140-day-old mice (n = 4).
(I) Western blot analysis for slMHC and slow troponin T (slTnT) using soleus muscle of 90-day-old mice. a-actinin is shown as a loading control.
(J) Relative mRNA levels of the slow skeletal muscle troponin I isoform (slTnI) in the soleus of 90-day-old mice as determined by qRT-PCR (n = 3).
Individual data points and bars (E, G, H, and J) represent means ± SEM. Scale bars = 50 mm (B and D), 2 mm (upper pictures, C), 250 nm (lower pictures, C), and
125 mm (F). p values are ***p < 0.001; **p < 0.01; *p < 0.05.Cell Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc. 417
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Role of mTORC1 and mTORC2 in Skeletal Musclebiochemically. In each experiment, at least three different mice
were compared with three littermate controls. Deletion of raptor
or rictor did not significantly affect the levels of mTOR (Figure 5A;
Table S1). The levels of rictor were not lowered in RAmKO mice,
and there was a slight decrease of raptor in RImKO mice (Fig-
ure 5A; Table S1). The amount of S6K, S6, and 4EBP1, which
are the main targets of mTORC1, was not changed in RAmKO
mice. However, phosphorylation of S6 and 4EBP1 was strongly
decreased (Figure 5A; Table S1). In RImKO mice, mTORC1 tar-
gets were not changed, but the level and activation state of
PKB/Akt and PKCa, which are both well-characterized sub-
strates of mTORC2 (Sarbassov et al., 2004, 2005), were lower.
More importantly, phosphorylation of PKB/Akt on residues
Thr308 and Ser473 was strongly increased in RAmKO mice
(Figure 5A; Table S1). Furthermore, the total amount of FoxO1
and FoxO3a was increased in RAmKO mice concomitant with
an increase in phosphorylation of FoxO1 on Thr24 (Figure 5A; Ta-
ble S1). In contrast, phosphorylation of FoxO1 on Ser316 and of
FoxO3a on Thr32 was not increased.
Activation of S6K by mTORC1 causes feedback inhibition of
the insulin/IGF1 pathway by affecting the levels and the phos-
phorylation of IRS-1 (Um et al., 2004; Harrington et al., 2004).
Consistent with this notion, deficiency of mTORC1 and thus ab-
sence of S6K/S6 activation abrogated this inhibitory feedback
and strongly increased IRS-1 levels in muscles of RAmKO
mice (Figure 5B; Table S1). Concomitant with the high protein
levels, IRS phosphorylation on Ser636 and Ser639 was in-
creased. On the other hand, there was no significant change in
either the levels or the phosphorylation of the mitogen-activated
Table 2. Analysis of the Contractile Properties of EDL and Soleus
Muscles of Control and RAmKO Mice
EDL Sol
ctrl RAmKO ctrl RAmKO
Twitch
Time to
peak (ms)
10.1 ± 0.9 11.1 ± 1.2 20.3 ± 4.2 39.7 ± 2.4***
Half time
to peak (ms)
3.0 ± 0.4 3.5 ± 0.5 5.6 ± 0.6 11.6 ± 1.1***
Half relaxation
time (ms)
15.5 ± 2.2 16.8 ± 3.3 30.8 ± 8.7 63.0 ± 5.1***
Absolute
force (mN)
54.0 ± 13.2 45.0 ± 9.7 30.0 ± 5.6 21.0 ± 8.1*
Tetanus
Half
contraction
time (ms)
16.6 ± 2.0 14.4 ± 1.1* 27.5 ± 5.4 41.0 ± 5.4***
Half relaxation
time (ms)
22.1 ± 1.3 24.1 ± 1.6* 55.2 ± 3.9 124.4 ± 13.2***
Absolute
force (mN)
311 ± 57.6 224 ± 38.1** 205 ± 20.8 164.0 ± 42.83
Specific force
(mN/mm2)
380.2 ± 57.2 328.3 ± 62.7 311.6 ± 56.3 264 ± 66.9
Datawere recorded fromEDL and soleusmuscles of 140-day-oldmice. p
values determined by Student’s t test are indicated by asterisks (n = 3 for
RAmKO and n = 4 for control mice). Values represent mean ± SD.418 Cell Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Iprotein kinases Erk1 and Erk2 (Figure 5B; Table S1). Thus, acti-
vation of PKB/Akt is probably due to the failure of raptor-
deficient muscle fibers to activate S6K and thus due to the
absence of the inhibitory feedback onto IRS. The release of
this feedback in muscle may require prolonged inactivation of
mTORC1 as phosphorylation of PKB/Akt was not increased after
8 hr treatment of cultured C2C12 myotubes with rapamycin and
was only slightly elevated after 16 hr (Figure S5C).
Next, we asked whether part of the phenotype of RAmKOmice
could be based on this hyperphosphorylation of PKB/Akt. To de-
termine whether PKB/Akt was indeed activated within muscle
fibers and not in non-muscle tissue of RAmKO mice, we stained
cross-sections of soleus muscle with antibodies specific for
PKB/Akt phosphorylated on Ser473 (P-PKB/AktS473). Indeed,
many of the muscle fibers were strongly positive for P-PKB/
AktS473 (FigureS5A). Akt/PKBhasbeen shown to regulate expres-
sion of atrogenes, called atrogin-1/MAFbx and MuRF-1, via the
FoxOs (Sandri et al., 2004; Stitt et al., 2004). As expected,
mRNA levels forbothatrogenesweresignificantly lower inRAmKO
mice than in controls (Figure 5C). A further target of PKB/Akt is gly-
cogen synthase kinase3b (GSK3b), which in turn inhibits glycogen
synthase (Sakamoto and Goodyear, 2002). Whereas the amount
of GSK3b was unaffected, phosphorylation of Ser9 was signifi-
cantly increased (Figure 5C; Table S1). Moreover, glycogen phos-
phorylase, which is the enzyme that generates free glucose from
glycogen, was downregulated (Figure 5C; Table S1). Thus, hyper-
phosphorylation of PKB/Akt in conjunctionwith downregulation of
glycogen phosphorylase is probably the basis for the increased
levels of glycogen observed in RAmKO mice.
In an attempt to identify the pathway that might underlie the
increased number of muscle fibers expressing slMHC, we found
a slight increase in the levels of calcineurin and a highly signifi-
cant increase in myocyte-enhancer factor 2A (Mef2A;
Figure 5C; Table S1). A slight, but not significant increase in
Mef2D was also observed. The increase in Mef2A is not a conse-
quence of the ongoing de- and regeneration in soleus muscle as
Mef2A was also increased in the least affected EDL muscle
(Figure S5B). In contrast to skeletal muscle in vivo, Mef2A and
slMHC were not increased in cultured C2C12 myotubes upon
prolonged treatment with rapamycin (Figure S5C).
Genes Involved in Mitochondrial Biogenesis
Are Downregulated in RAmKO Mice
One of themost striking features of RAmKO skeletal muscle is its
lower oxidative capacity that is probably due to ultrastructural
changes and loss of mitochondria. Thus, we also tested whether
genes involved in mitochondrial biogenesis were affected by the
deletion of raptor. Recent evidence indicates a function of
mTORC1 in the regulation of mitochondrial function via PGC1a
(Cunningham et al., 2007). Consistent with these findings, tran-
script levels for PGC1a and for its target gene myoglobin were
significantly reduced in RAmKO muscle (Figure 5E). Moreover,
the protein levels of the PGC1a coactivator PPARg and themito-
chondrial marker cytochrome c oxidase IV (COX IV) were signif-
icantly decreased in RAmKO mice (Figure 5F; Table S1). These
results are consistent with the low oxidative capacity of muscle
from RAmKO mice, and they support the notion that this is due
to loss of PGC1a.nc.
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To test whether the hyperactivated state of PKB/Akt in RAmKO
mice can be prevented by additional deletion of rictor, we gener-
ated double floxed mice and mated those with HSA-Cre mice.
The resulting mice, called DmKO, lacked both raptor and rictor
in skeletal muscle (Figure 5G; Table S1). Their overall phenotype
was indistinguishable from RAmKO mice (data not shown). Like
in RAmKO mice, skeletal muscle of DmKO mice contained high
levels of glycogen and was less oxidative (Figure 5H). Levels of
mTOR were significantly lower in DmKO mice than in either of
the single knockouts (Figure 5G; Table S1). As mTORC2 was
shown to phosphorylate PKB/Akt on Ser473 (Sarbassov et al.,
2005), we also tested the activation state of PKB/Akt in DmKO
muscle. As shown in Figure 5G and in Table S1, PKB/Akt was still
hyperphosphorylated on Thr308 and Ser473 in DmKO mice.
Again, phosphorylation of PBK/Akt occurred only in muscle
fibers and not in non-muscle tissue (Figure 5J). In summary,
these results indicate that mTORC2 is not the only kinase that
phosphorylates PKB/Akt on Ser473.
DISCUSSION
Our work dissects the role of raptor and rictor (i.e., mTORC1 and
mTORC2, respectively) in skeletal muscle. The HSA-Cre mice
used for our experiments start to express Cre at the earliest
stages of skeletal muscle development when the first myotubes
are formed. In fully developed muscle, Cre is exclusively ex-
pressed in skeletal muscle fibers but not in non-muscle cells,
such as Schwann cells, fibroblasts, or satellite cells (Schwander
et al., 2003). Neither RAmKO nor RImKO mice showed any ab-
normalities at birth, indicating that mTORC1 and mTORC2 are
not essential for muscle development. Whereas no overt pheno-
type was detected in RImKO mice throughout adulthood, which
is consistent with another report (Kumar et al., 2008), RAmKO
mice developed a progressive dystrophy and ultimately died
around the age of 5 months. Interestingly, DmKO mice showed
very similar pathological changes as RAmKO mice, indicating
that mTOR function in skeletal muscle requires only mTORC1.
The dystrophy in RAmKOmice did not affect all muscles to the
same extent. For example, diaphragm and soleus muscles were
severely affected while EDL showed many fewer changes.
Prominent features of the dystrophy were elevated numbers of
muscle fibers with centralized nuclei and the presence of central
core-like structures. Central cores are hallmarks of ‘‘central core
diseases,’’ which are inherited neuromuscular disorders with
a myopathic syndrome. The most frequent causes of this group
of diseases are mutations in the ryanodine receptor, which is the
main protein responsible for calcium homeostasis in muscle (re-
viewed in Treves et al., 2008). Thus, the similarity of the pathol-
ogy in RAmKO to this class of disease suggests that mishandling
of intracellular calcium may underlie the disease. The low levels
of PGC1a may additionally contribute to the dystrophic pheno-
type of RAmKOmice as conditional ablation ofPGC1a in skeletal
muscle results in a myopathic phenotype (Handschin et al.,
2007). Finally, several metabolic diseases that cause accumula-
tion of glycogen in skeletal muscle, such as Pompe’s and
McArdle’s diseases, affect skeletal muscle function. The most
severely affected patients may even die because of respiratory
distress (Winkel et al., 2005). In summary, RAmKO mice showCellchanges in muscle homeostasis that together may lead to the
progressive muscle dystrophy.
Raptor Is Required for High Oxidative Capacity
of Skeletal Muscle
We found that the severity of the muscle dystrophy correlated
with the relative levels of raptor, rictor, mTOR, and PKB/Akt in
particular muscles. Interestingly, the most affected muscles,
such as soleus or diaphragm, are also those that are insulin sen-
sitive (Song et al., 1999) and contain a high number of slow-
twitch, oxidative fibers. Biochemical and morphological analysis
showed that soleus muscle expressed little of the oxygen carrier
myoglobin and of COX IV and contained fewer and misshaped
mitochondria. A direct role of mTOR and raptor for the function
of mitochondria has recently been suggested using cultured
Jurkat cells (Schieke et al., 2006). Moreover, mTOR has been
shown to form a complex with PGC1a (Cunningham et al.,
2007), which together with its cofactor PPARg is a key regulator
of mitochondrial biogenesis and function. Consistent with a reg-
ulatory function of mTORC1 for mitochondria, mRNA levels for
PGC1a and protein levels of PPARg were decreased in RAmKO
mice. Furthermore, mRNA and protein levels of target genes for
PGC1a/PPARg, such as myoglobin (Lin et al., 2002) and glyco-
gen phosphorylase (Wende et al., 2007), were also reduced in
RAmKO mice. Also, very similar to the phenotype of RAmKO
mice, a reduced intermyofibrillar mitochondrial content in
slow-twitch muscles has been reported in PGC1a knockout
mice (Leone et al., 2005). In summary, our data indicate that
mTORC1 is essential for the function of mitochondria in skeletal
muscle, and they link mTORC1 to the regulation of PGC1a
in vivo.
Segregation of Metabolic and Structural Properties
in Skeletal Muscle of RAmKO Mice
Despite the loss of oxidative capacity and the downregulation of
PGC1a, expression of slow structural proteins (slSP; Figure 5K)
was increased in RAmKOmice. Analysis of themechanical prop-
erties in EDL and soleusmuscle further confirmed that bothmus-
cles adapt characteristics indicative of slow-twitch fibers. These
results suggest that RAmKO mice induce a structural program
for slow-twitch fibers. As muscle-specific inactivation of
PGC1a causes a fiber-type switch to fast-contracting muscle
fibers (Handschin et al., 2007) and transgenic overexpression
causes an increase in oxidative muscle (Lin et al., 2002), we
also testedwhether any other pathways that affectmuscle differ-
entiation were altered in the RAmKO mice. Besides PGC1a, the
best characterized factors involved in fiber-type determination
are calcineurin/NFAT and the Mef2 transcription factors (Bas-
sel-Duby and Olson, 2006). Of those candidate genes, the levels
of calcineurin and in particular of Mef2A and Mef2D were in-
creased in RAmKO mice. Thus, facilitated Mef2-mediated tran-
scription may be the basis for the increased levels of slSP de-
spite the low levels of PGC1a. Opposite regulation of PGC1a
and Mef2A has also been seen in cultured cells when treated
with rapamycin (Cunningham et al., 2007). Mef2 has also been
shown to be dominant in the regulation of muscle fiber type as
transgenic overexpression of a constitutively active form of
Mef2 is sufficient to increase the number of slow muscle fibers
(Potthoff et al., 2007). Mef2 is generally thought to be controlledMetabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc. 419
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kinase IV (Wu et al., 2000). In this context it is interesting to note
that the increase of the half-relaxation time in RAmKO muscles
may result from a lower removal rate of calcium from the myo-
plasm by the sarcoplasmic reticulum (Gollnick et al., 1991).
This prolonged presence of intracellular calcium during contrac-
tile activity might contribute to the activation of calcium-depen-
dent signaling pathways and thus to the upregulation of slSP
(Figure 5K). On the other hand, it is possible thatMef2 expression
is increased because of hyperactivation of PKB/Akt (Wiedmann
et al., 2005). Consistent with this notion, failure to induce a pro-
nounced phosphorylation of PKB/Akt in cultured C2C12 myo-
tubes by treatment with rapamycin coincided with unchanged
levels of Mef2A and slMHC (Figure S5C).
Raptor Deficiency Affects Protein Synthesis Directly
and PKB/Akt Activation Indirectly
Ablation of mTORC1 in skeletal muscles prevented phosphory-
lation of S6K/S6 and 4EBP1. This branch of the mTOR signaling
pathway is characterized best and has been shown to directly
control protein synthesis. Impaired efficacy of protein synthesis
in postnatal muscle might also be the reason for the muscles
being lighter in RAmKO mice. This effect may also contribute
to the shift in fiber size distribution toward smaller values. Our
data thus implicate mTORC1 in the maintenance of mass even
in fully innervated muscle. Therefore, they extend previous
results in which mTOR inhibition by rapamycin was shown to
prevent compensatory hypertrophy and recovery from atrophy
but not to cause atrophy (Bodine et al., 2001). Our results are
also consistent with the findings that skeletal muscles of
S6K1-deficient mice are atrophic (Ohanna et al., 2005). The dif-
ference in weight of the RAmKOmice became significant only af-
ter the age of approximately 2 months, suggesting that the ab-
sence of raptor might be compensated for during early periods
of muscle growth. One compensatory mechanism could be
PKB/Akt-mediated phosphorylation of GSK3b as inhibition of
GSK3b has been shown to cause hypertrophy in cultured
C2C12 myotubes (Rommel et al., 2001). We also provide evi-
dence that the lack of S6K activation in RAmKO mice is respon-
sible for the hyperphosphorylation of PKB/Akt on Thr308 and
Ser473 as levels of IRS-1 were highly increased. Activation of
S6K has been shown to decrease the levels of IRS-1 (reviewed
in Manning, 2004). Interestingly, the same hyperactivation of
PKB/Akt is seen in mice with an adipocyte-specific ablation of
raptor (Polak et al., 2008).CellRaptor-Deficient Skeletal Muscles Are Small, despite
High Energy Consumption
Whereas changes in mitochondrial content and function might
be based on a direct influence of mTORC1 (Figure 5K), other as-
pects such as the loss of adipose tissue are probably a conse-
quence of the hyperactivation of PKB/Akt. Muscle-specific over-
expression of a constitutively active form of PKB/Akt causes
pronounced hypertrophy (Izumiya et al., 2008). Concomitantly
with the hypertrophy, mice are lean and do not become obese
on a high-fat diet (Izumiya et al., 2008). In the RAmKO mice,
PKB/Akt was hyperactive resulting in mice that had much less
fat than control mice on a normal chow diet (Table 1) or on
a high-fat diet (K.R., C.F.B., and M.A.R., unpublished observa-
tion). In contrast to mice that express the constitutively active
form of PKB/Akt, lack of mTORC1 prevented the ‘‘translation’’
of PKB/Akt activation into muscle hypertrophy in RAmKO
mice. Thus, RAmKO mice behave metabolically like mice that
overexpress activated PKB/Akt but lack the hypertrophic effect
on muscle. We hypothesize that the metabolic phenotype of be-
ing lean is due to the high need of muscles for glucose because
of their high glycogen storage capability and their low capacity
for oxidative phosphorylation. If the muscle of RAmKO mice
acts as such a global glucose sink, non-muscle tissues may
have to use alternative energy sources such as fatty acids.
This, in turn, could result in an increased release andmobilization
of fatty acids from adipose tissue. The high content of glycogen
is probably based on the hyperactivation of PKB/Akt, which in-
hibits GSK3b, which in turn releases inhibition of glycogen syn-
thase (Figure 5H). In addition, inhibition of GSK3b also lowers
phosphorylation of NFATc and thus prolongs its activity in the
nucleus (Beals et al., 1997). NFATc transcription factors, which
are also targets of calcineurin (see above), are known to contrib-
ute to fiber type selection (reviewed in Wu et al., 2007). Thus,
changes in NFATc activity may add to the expression of struc-
tural proteins indicative of slow-twitch muscle.
Hyperactivation of PKB/Akt Does Not Require
rictor/mTORC2
Our data strongly indicate that the absence of the S6K-mediated
inhibitory feedback caused phosphorylation of PKB/Akt on
Thr308 and Ser473 in RAmKO mice. While phosphorylation on
Thr308 is mediated by 3-phosphoinositide-dependent kinase
(PDK1; Alessi et al., 1997), mTORC2 has been shown to phos-
phorylate PKB/Akt on Ser473 (Sarbassov et al., 2005). Consis-
tent with such a role for mTORC2, we and others observed aFigure 5. Biochemical Characterization
(A, B, D, and F) Western blot analysis of soleus muscle from 90-day-old RAmKO, RImKO, and control mice using antibodies directed against the proteins indi-
cated (for details see Experimental Procedures). Equal amount of protein was loaded in each lane. Antibodies to a-actinin and PI3K were in addition used as
loading controls.
(C and E) Relative mRNA levels of MuRF1, MAFbx, myoglobin (myogl.), and PGC1a in soleus muscle of 90-day-old RAmKO or control mice. Values obtained in
controls were set to 100% (n = 3).
(G and I) Western blot analysis of soleus muscle from 60-day-old DmKO and control mice.
(H) PAS and NADH-TR staining on cross-sections of triceps muscles from 50-day-old DmKO and control mice.
(J) Immunostaining with antibodies specific for P-PKB/AktS473 using cross-sections of 60-day-old DmKO and control mice.
(K) Schematic of the interactions contributing to the phenotype of RAmKOmice. Signaling pathway downstream of the insulin/IGF receptor is shown. Blue arrows
with open arrowheads represent interactions that affect gene transcription; black symbols represent regulation on the protein level that activates or inhibits the
targets. Abbreviations are as follows: atg: atrogenes (MuRF1 and MAFbx); GP: glycogen phosphorylase; GS: glycogen synthase; IGF-R: IGF receptor; Mb:
myoglobin; slSP: slow structural proteins.
Data (C and E) represent means ± SEM. Scale bars (H and J): 50 mm. p values are **p < 0.01; *p < 0.05.Metabolism 8, 411–424, November 5, 2008 ª2008 Elsevier Inc. 421
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(Figure 5; Shiota et al., 2006; Guertin et al., 2006; Kumar et al.,
2008). We now show that, unexpectedly, muscles from mice
lacking both mTORC1 and mTORC2 still showed a marked in-
crease in PKB/Akt phosphorylation on both Thr308 and
Ser473. Thus, mTORC2 is not required to phosphorylate PKB/
Akt on Ser473 in vivo, indicating that skeletal muscles express
a PDK2 distinct from mTORC2. A candidate for this kinase is
DNA-dependent protein kinase (DNA-PK), which has been
shown to phosphorylate PKBa/Akt1 in cells that are deficient
for rictor in response to DNA damage (Bozulic et al., 2008).
DNA-PK and PKB/Akt are localized in the nucleus of embryonic
fibroblasts upon DNA damage (Bozulic et al., 2008). However,
PKB/Akt phosphorylated on Ser473 in DmKO mice was ex-
pressed along the sarcolemma and not specifically localized in
myonuclei. Several additional proteins have been postulated to
act as PDK2, some of which are expressed in skeletal muscle
and are localized to the sarcolemma (see Bayascas and Alessi,
2005 for a review).
In summary, our data show that mTORC1 is important for the
function and maintenance of skeletal muscle. We provide evi-
dence that the different aspects of the phenotype observed in
RAmKO mice are probably based on the direct effect of
mTORC1 on its downstream targets S6K and 4EBP1, on the
function of mTORC1 to regulate mitochondrial biogenesis and
function via PGC1a, or on an indirect effect on its upstream com-
ponent PKB/Akt. Our data also suggest that long-term treatment
with high doses of rapamycin may have detrimental effects on
muscle function.
EXPERIMENTAL PROCEDURES
Antibodies
Rabbit polyclonal antibodies are as follows: 4E-BP1 (Phas-I) from Zymed,
ERK1&2 pan and ERK1&2 (pTpY185/187) from Biosource, FoxO1a and
FoxO1a (phospho S319) from Abcam, P-PKCa (Ser657) and Troponin T-SS
(H-55) from Santa Cruz, Phospho-4E-BP1 (Ser65), PAN-actin, Akt, Phos-
pho-Akt (Thr308), Pan-Calcineurin A, Phospho-FoxO1 (Thr24)/FoxO3a
(Thr32), Phospho-GSK-3b (Ser9), Phospho-IRS-1 (S636/639), MEF2A,
mTOR, PKCa, S6 Ribosomal Protein, Phospho-S6 Ribosomal Protein
(Ser235/236), and p70 S6 kinase from Cell Signaling. Rabbit monoclonal an-
tibodies are as follows: b-actin, Phospho-Akt (Ser473), Cox IV, FoxO3a
(75D8), GSK-3b, IRS-1, PI3 Kinase p85, Raptor, and Rictor from Cell Signaling
and PPARg from Santa Cruz. Mouse monoclonal antibodies are as follows:
a-actinin and myosin (skeletal, slow) from sigma and b-tubulin and Mef2D
from BD Biosciences. Goat polyclonal antibody are as follows: GP from
Santa Cruz.
Tissue Homogenization, Immunoprecipitation, SDS-PAGE,
and Western Blot
Muscles frozen in liquid nitrogen were powdered on dry ice, then transferred to
cold RIPA buffer supplemented with 1% Triton-X, 10% glycerol, protease in-
hibitor cocktail tablets (Roche), and phosphatase inhibitor cocktail I and II
(Sigma). Cell lysates were incubated on ice for 2 hr, sonicated two times for
15 s and centrifuged at 13,600 g for 30 min at 4C. Cleared lysates were
then used to determine total protein levels (BCA Protein Assay, Pierce). After
dilution with sample buffer, equal protein amounts were loaded onto SDS gels.
Histology and Immunohistochemistry
Muscles frozen in liquid nitrogen-cooled isopentane were fixed with 2% PFA
and cut into 12 mm cross-sections. Cross-sections were permeabilized with
1% Triton/PBS for 5 min, washed with 100 mM glycine/PBS for 15 min,
blocked with 1%BSA/PBS for 30min, and incubated with specific primary an-422 Cell Metabolism 8, 411–424, November 5, 2008 ª2008 Elseviertibody overnight at 4C. Samples were subsequently washed with 1% BSA/
PBS, three times for 1 hr, stained with appropriate fluorescently labeled sec-
ondary antibodies for 1 hr at room temperature. After washing with PBS, sam-
ples were mounted with Citifluor (Citifluor Ltd). General histology on cross-
sections was performed using hematoxylin and eosin (H&E; Merck, Rayway,
NJ, USA). NADH staining was done as described (Dunant et al., 2003). Periodic
acid-Schiff staining (PAS staining system, Sigma) was performed according to
the manufacturer’s instruction. After H&E, NADH, and PAS staining, samples
were dehydrated and mounted with DePeX mounting medium (Gurr, BDH).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, five fig-
ures, and one table and can be found with this article online at http://www.
cellmetabolsim.org/supplemental/S1550-4131(08)00320-3.
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